Graham Capital Management L.P. Increases Holdings in Evolus, Inc. (NASDAQ:EOLS)

Graham Capital Management L.P. lifted its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 289.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,963 shares of the company's stock after acquiring an additional 34,907 shares during the quarter. Graham Capital Management L.P. owned approximately 0.07% of Evolus worth $518,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. raised its stake in shares of Evolus by 9.8% in the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock worth $368,000 after purchasing an additional 2,989 shares during the last quarter. Barclays PLC increased its position in shares of Evolus by 12.9% during the fourth quarter. Barclays PLC now owns 105,786 shares of the company's stock worth $1,167,000 after acquiring an additional 12,124 shares during the period. Frontier Capital Management Co. LLC acquired a new stake in Evolus in the fourth quarter valued at $2,648,000. Raymond James Financial Inc. purchased a new stake in Evolus in the fourth quarter valued at approximately $575,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock worth $2,753,000 after purchasing an additional 65,972 shares during the period. Institutional investors own 90.69% of the company's stock.

Evolus Trading Down 0.6%

Shares of EOLS traded down $0.06 on Wednesday, reaching $9.90. 112,570 shares of the company's stock were exchanged, compared to its average volume of 687,219. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market capitalization of $638.31 million, a P/E ratio of -10.77 and a beta of 1.11. The business has a 50 day moving average price of $11.19 and a two-hundred day moving average price of $12.24. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82.

Analyst Ratings Changes

EOLS has been the topic of several recent research reports. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. BTIG Research initiated coverage on shares of Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $23.75.

Insider Buying and Selling at Evolus

In related news, insider Rui Avelar sold 27,904 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares in the company, valued at $4,806,312.42. This represents a 7.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Moatazedi sold 6,251 shares of the stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the sale, the insider now owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. The trade was a 1.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,241 shares of company stock worth $1,048,666 over the last quarter. 5.90% of the stock is currently owned by insiders.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.